Grifols SA (GRFS)
9.545
+0.48
(+5.24%)
USD |
NASDAQ |
Nov 14, 16:00
9.545
0.00 (0.00%)
After-Hours: 20:00
Grifols Enterprise Value: 8.218B for Nov. 13, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 13, 2024 | 8.218B |
| November 12, 2024 | 8.238B |
| November 11, 2024 | 8.387B |
| November 08, 2024 | 8.503B |
| November 07, 2024 | 8.510B |
| November 06, 2024 | 8.204B |
| November 05, 2024 | 8.367B |
| November 04, 2024 | 8.034B |
| November 01, 2024 | 8.061B |
| October 31, 2024 | 7.959B |
| October 30, 2024 | 8.014B |
| October 29, 2024 | 7.626B |
| October 28, 2024 | 7.721B |
| October 25, 2024 | 7.986B |
| October 24, 2024 | 8.075B |
| October 23, 2024 | 8.054B |
| October 22, 2024 | 8.048B |
| October 21, 2024 | 7.878B |
| October 18, 2024 | 7.932B |
| October 17, 2024 | 7.891B |
| October 16, 2024 | 7.823B |
| October 15, 2024 | 7.837B |
| October 14, 2024 | 7.885B |
| October 11, 2024 | 7.891B |
| October 10, 2024 | 7.919B |
| Date | Value |
|---|---|
| October 09, 2024 | 7.939B |
| October 08, 2024 | 8.007B |
| October 07, 2024 | 8.088B |
| October 04, 2024 | 8.116B |
| October 03, 2024 | 8.136B |
| October 02, 2024 | 8.061B |
| October 01, 2024 | 8.054B |
| September 30, 2024 | 8.088B |
| September 27, 2024 | 16.77B |
| September 26, 2024 | 16.66B |
| September 25, 2024 | 16.57B |
| September 24, 2024 | 16.60B |
| September 23, 2024 | 16.66B |
| September 20, 2024 | 16.77B |
| September 19, 2024 | 16.85B |
| September 18, 2024 | 16.62B |
| September 17, 2024 | 16.73B |
| September 16, 2024 | 16.96B |
| September 13, 2024 | 16.98B |
| September 12, 2024 | 16.88B |
| September 11, 2024 | 16.94B |
| September 10, 2024 | 16.40B |
| September 09, 2024 | 16.51B |
| September 06, 2024 | 16.45B |
| September 05, 2024 | 16.72B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
7.626B
Minimum
Oct 29 2024
24.17B
Maximum
Feb 21 2020
18.32B
Average
17.87B
Median
Jun 24 2022
Enterprise Value Benchmarks
| Cellectis SA | -18.38M |
| Adaptimmune Therapeutics PLC | 6.629M |
| Akari Therapeutics PLC | 23.60M |
| Biodexa Pharmaceuticals PLC | -3.094M |
| Verona Pharma PLC | 2.807B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 56.85M |
| Revenue (Quarterly) | 1.972B |
| Total Expenses (Quarterly) | 1.621B |
| EPS Diluted (Quarterly) | 0.0836 |
| Gross Profit Margin (Quarterly) | 40.53% |
| Profit Margin (Quarterly) | 2.88% |
| Earnings Yield | 3.32% |
| Operating Earnings Yield | 17.54% |
| Normalized Earnings Yield | 3.643 |